期刊文献+

肝病患者血清和腹水CA125水平变化 被引量:4

下载PDF
导出
摘要 目的 探讨肝炎、肝硬化代偿期、肝硬化失代偿期、肝癌患者血清肿瘤抗原 12 5 (CA12 5 )水平与肝损害的关系。方法 采用放射免疫分析法检测 2 0例正常对照、3 0例肝炎患者、2 0例肝硬化代偿期患者、3 0例肝硬化失代偿期患者、2 5例肝癌患者血清CA12 5水平 ,并比较 2 5例肝硬化患者腹水CA12 5值与血清CA12 5值的相关性。结果 肝炎组、肝硬化代偿期组、肝硬化失代偿期组、肝癌组患者血清CA12 5值均显著高于对照组 (P <0 .0 5 ) ;肝硬化失代偿期组患者血清CA12 5值显著高于肝硬化代偿期组 (P <0 .0 1) ,肝癌组患者血清CA12 5值明显高于肝硬化失代偿期组 (P <0 .0 1)。 2 5例肝硬化患者腹水CA12 5值显著高于血清CA12 5值 ,二者之间呈线性相关 (r =0 .766,P <0 .0 0 1)。结论 肝硬化患者血清CA12 5水平升高及升高程度与肝病严重程度密切相关 ,血清CA12 5水平可作为反映肝病患者肝损害程度的指标之一 ,同时血清CA12 5水平可能成为监测肝硬化患者腹水消长的一项有用指标。
出处 《现代医学》 2004年第5期339-340,共2页 Modern Medical Journal
  • 相关文献

参考文献9

  • 1WHITEHOUSE C, SOLOMON E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening[J]. Gynecol Oncol,2003,88(1Pt 2):S152-157. 被引量:1
  • 2GUPPY A E,RUSTIN G J. CA125 response: can it replace the traditional response criteria in ovarian cancer-[J]. Oncologist, 2002,7(5):437-443. 被引量:1
  • 3TSUDA H, HASHIGUCHI Y, NAKATA S, et al. The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer[J]. Int J Gynecol Cancer, 2002,12(5):435-437. 被引量:1
  • 4SIMSEK H, KADAYIFCI A, OKAN E. Importance of serum CA125 levels in malignant peritoneal mesothelioma[J]. Tumour Biol, 1996,17(1):1-4. 被引量:1
  • 5TOPALAK O, SAYGILI U, SOYTURK M, et al. Serum, pleural effusion, and ascites CA125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study[J]. Gynecol Oncol,2002,85(1):108-113. 被引量:1
  • 6MAVLIGIT G M, ESTROV Z. CA125: a clinically useful tumor marker in the management of colorectal carcinoma metastatic to the liver in patients with normal carcinoembryonic antigen[J]. Am J Clin Oncol, 2000,23(2):213-215. 被引量:1
  • 7MOLINA R, FILELLA X, BRUIX J,et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases[J]. Clin Chem, 1991,37(8):1379-1383. 被引量:1
  • 8肖文斌,刘玉兰.肝硬化患者血清和腹水CA125升高[J].世界华人消化杂志,2003,11(11):1720-1722. 被引量:22
  • 9ZUCKERMAN E, LANIR A, SABO E, et al. Cancer antigen 125: a sensitive marder of ascites in patients with liver cirrhosis[J]. Am J Gastroenterol, 1999,94(6):1613-1618. 被引量:1

二级参考文献24

  • 1Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol 2003;88(1 Pt 2):S152-157 被引量:1
  • 2Guppy AE, Rustin GJ. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 2002;7:437-443 被引量:1
  • 3Tsuda H, Hashiguchi Y, Nakata S, Deguchi M, Negoro S,Ishiko O, Yamamoto K. The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer. Int J Gynecol Cancer 2002;12:435-437 被引量:1
  • 4Simsek H, Kadayifci A, Okan E. Importance of serum CA 125levels in malignant peritoneal mesothelioma. Tumour Biol 1996;17:1-4 被引量:1
  • 5Topalak O, Saygili U, Soyturk M, Karaca N, Batur Y, Uslu T,Erten O. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases:a comparative study. Gynecol Oncol 2002;85:108-113 被引量:1
  • 6Mavligit GM, Estrov Z. CA 125: a clinically useful tumor marker in the management of colorectal carcinoma metastatic to the liver in patients with normal carcinoembryonic antigen.Am J Clin Oncol 2000;23:213-215 被引量:1
  • 7Walach N, Gur Y. Leukocyte alkaline phosphatase, CA15-3,CA125, and CEA in cancer patients. Tumori 1998;84:360-363 被引量:1
  • 8Meden H, Fattahi-Meibodi A. CA 125 in benign gynecological conditions. Int J Biol Markers 1998;13:231-237 被引量:1
  • 9Cioffi M, Fratta M, Gazzerro P, Di Finizio B, Tucci A, Molinari AM.OVCA (CA125) second generation: technical aspects and serum levels in controls, patients with liver disease, pregnant women and patients with ovarian disease. Tumori 1997;83:594-598 被引量:1
  • 10Kadayifci A, Simsek H, Savas MC, Toppare M. Serum tumor markers in chronic liver disease. Neoplasma 1996;43:17-21 被引量:1

共引文献21

同被引文献17

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部